Treatment and Clinical Outcomes Among SLE Patients in Pregnancy: A Real World Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age. Compared with healthy pregnant women, SLE patients have higher incidence of premature delivery, preeclampsia and fetal loss during pregnancy. Since SLE patients usually have disease activity during pregnancy and postpartum, and a variety of maternal and fetal diseases are closely related to SLE, it is very important to monitor the disease activity and drug treatment of SLE patients during pregnancy.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 20
Maximum Age: 45
Healthy Volunteers: f
View:

• Patients diagnosed with systemic lupus erythematosus (SLE) (ACR criteria, 1997);

• Pregnant women aged 20-45 years old;

• Willing to participate in this study, willing to medication and follow-up according to the treatment plan, and sign the informed consent.

Locations
Other Locations
China
Qilu Hospital
RECRUITING
Jinan
Contact Information
Primary
Qiang Shu, Dr.
shuqiang@sdu.edu.cn
0086-0531-82169654
Backup
Yunfei Guo, Bachelor
guoyunfei@mail.sdu.edu.cn
0086-0531-82169654
Time Frame
Start Date: 2018-01-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 200
Treatments
Experimental: combined with aPL(+)
the antiphospholipid antibodies appear in blood at least once
Experimental: combined with aPL(-)
the antiphospholipid antibodies never appear in blood
Sponsors
Leads: Qilu Hospital of Shandong University

This content was sourced from clinicaltrials.gov